Could US FDA User Fee Bill Include The Long-Sought 505(b)(2) Pathway For Biosimilars?

 
• By Derrick Gingery

Former FDA official says the pathway is needed to avoid wasted sponsor time and effort.

Road construction
Congress could consider creating a 505(b)(2)-like pathway for biosimilars in upcoming FDA-focused legislation. • Source: Alamy

More from Biosimilars

More from Biosimilars & Generics